Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.

British journal of cancer - 1 Oct 2023

Belli Stefania, Pesapane Ada, Servetto Alberto, Esposito Daniela, Napolitano Fabiana, Ascione Claudia Maria, Allotta Alessandra, Zambrano Nicola, Marino Federica Zito, Franco Renato, Troiani Teresa, Formisano Luigi, Bianco Roberto

Abstract excerpt

BACKGROUND: The identification of novel therapeutic strategies for metastatic colorectal cancer (mCRC) patients harbouring KRAS mutations represents an unmet clinical need. In this study, we aimed to clarify the role of p21-activated kinases (Paks) as therapeutic target for KRAS-mutated CRC. METHODS: Paks expression and activation levels were evaluated in a cohort of KRAS-WT or -mutated CRC patients by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to p21-Activated Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 37568037
DOI: 10.1038/s41416-023-02390-z
PMCID: PMC10539494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.PMID 37568037Read ↗

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.Semantic proximity Read ↗

Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.Semantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.Semantic proximity Read ↗

Therapeutic Potential of Targeting PAK SignalingSemantic proximity Read ↗

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cellsSemantic proximity Read ↗

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.Semantic proximity Read ↗

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.Semantic proximity Read ↗

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.Semantic proximity Read ↗

Emerging functions of p21‐activated kinases in human cancer cellsSemantic proximity Read ↗

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.